GlassScriptPhysician profile
Nabeel I Babar
NPI 1942478961
$11,676.60
in general payments reported to CMS, 2019-2025
41 companies · $586 in 2025
The $586 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,763 · 2020: $625 · 2021: $704 · 2022: $824 · 2023: $787 · 2024: $388 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705 · Education: $55.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,705.43 |
| Education | $55.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $7,685.17 | 2019-2020 | |
| Lilly USA, LLC | $657.01 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $517.87 | 2020-2025 | Ozempic, Rybelsus |
| Ibsa Pharma INC. | $358.08 | 2021-2025 | Tirosint, Licart, Flector |
| Astrazeneca Pharmaceuticals LP | $246.89 | 2019-2022 | |
| Pfizer INC. | $170.96 | 2023 | |
| Insulet Corporation | $151.57 | 2022-2025 | Omnipod |
| Corcept Therapeutics | $139.36 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.40 | 2023-2025 | |
| Dexcom, INC. | $133.50 | 2022-2023 | Dexcom G7 Gss (161) |
| Biogen, INC. | $103.90 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $103.46 | 2021-2025 | Recorlev |
| Abbott Laboratories | $103.07 | 2020-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $100.18 | 2021-2025 | Minimed 780g |
| Inari Medical, INC. | $95.61 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabeel Babar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.